CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 262 filers reported holding CLOVIS ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,841,000 | +100.9% | 114,460 | +45.4% | 0.25% | +66.4% |
| Q4 2018 | $1,414,000 | -31.1% | 78,737 | +216.0% | 0.15% | +7.0% |
| Q3 2017 | $2,053,000 | +18.6% | 24,917 | +34.9% | 0.14% | +16.4% |
| Q2 2017 | $1,731,000 | -2.4% | 18,477 | -33.7% | 0.12% | -2.4% |
| Q1 2017 | $1,774,000 | -57.3% | 27,864 | -38.3% | 0.12% | -58.1% |
| Q3 2015 | $4,151,000 | +34.7% | 45,136 | +28.7% | 0.30% | +51.3% |
| Q2 2015 | $3,081,000 | -10.4% | 35,063 | -24.3% | 0.20% | -8.4% |
| Q1 2015 | $3,438,000 | +6.1% | 46,312 | -20.0% | 0.22% | +5.9% |
| Q4 2014 | $3,240,000 | +37.1% | 57,859 | +11.0% | 0.20% | +37.2% |
| Q3 2014 | $2,364,000 | +13.2% | 52,116 | +3.3% | 0.15% | +20.3% |
| Q2 2014 | $2,089,000 | -36.4% | 50,446 | +6.4% | 0.12% | -54.6% |
| Q1 2014 | $3,285,000 | – | 47,429 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
| EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
| Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
| NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
| Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
| Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
| PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
| HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |